A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis. / Fischer, B M; Mortensen, J; Langer, S W; Loft, A; Berthelsen, A K; Petersen, B I; Daugaard, G; Lassen, U; Hansen, H H.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 18, Nr. 2, 02.2007, s. 338-45.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A prospective study of PET/CT in initial staging of small-cell lung cancer
T2 - comparison with CT, bone scintigraphy and bone marrow analysis
AU - Fischer, B M
AU - Mortensen, J
AU - Langer, S W
AU - Loft, A
AU - Berthelsen, A K
AU - Petersen, B I
AU - Daugaard, G
AU - Lassen, U
AU - Hansen, H H
PY - 2007/2
Y1 - 2007/2
N2 - BACKGROUND: Small-cell lung cancer (SCLC) accounts for 15%-20% of all lung cancer cases. Accurate and fast staging is mandatory when choosing treatment, but current staging procedures are time consuming and lack sensitivity.PATIENTS AND METHODS: A prospective study was designed to examine the role of combined positron emission tomography/computed tomography (PET/CT) compared with standard staging (CT, bone scintigraphy and immunocytochemical assessment of bone marrow biopsy) of patients with SCLC. Thirty-four consecutive patients were included. Twenty-nine patients received initial PET/CT.RESULTS: PET/CT caused change of stage in 5/29 (17%). Excluding patients with unconfirmed findings or pleural effusion, the sensitivity for accurate staging of patients with extensive disease was the following: for standard staging 79%, PET 93% and PET/CT 93%. Specificity was 100%, 83% and 100%, respectively.CONCLUSION: The results from this first study on PET/CT in SCLC indicates that PET/CT can simplify and perhaps even improve the accuracy of the current staging procedure in SCLC. A larger clinical trial, preferably with consequent histological confirmation in case of discordance, however, is warranted.
AB - BACKGROUND: Small-cell lung cancer (SCLC) accounts for 15%-20% of all lung cancer cases. Accurate and fast staging is mandatory when choosing treatment, but current staging procedures are time consuming and lack sensitivity.PATIENTS AND METHODS: A prospective study was designed to examine the role of combined positron emission tomography/computed tomography (PET/CT) compared with standard staging (CT, bone scintigraphy and immunocytochemical assessment of bone marrow biopsy) of patients with SCLC. Thirty-four consecutive patients were included. Twenty-nine patients received initial PET/CT.RESULTS: PET/CT caused change of stage in 5/29 (17%). Excluding patients with unconfirmed findings or pleural effusion, the sensitivity for accurate staging of patients with extensive disease was the following: for standard staging 79%, PET 93% and PET/CT 93%. Specificity was 100%, 83% and 100%, respectively.CONCLUSION: The results from this first study on PET/CT in SCLC indicates that PET/CT can simplify and perhaps even improve the accuracy of the current staging procedure in SCLC. A larger clinical trial, preferably with consequent histological confirmation in case of discordance, however, is warranted.
KW - Aged
KW - Bone Marrow
KW - Bone Neoplasms
KW - Carcinoma, Small Cell
KW - Female
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Lung Neoplasms
KW - Male
KW - Middle Aged
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Prospective Studies
KW - Radiopharmaceuticals
KW - Sensitivity and Specificity
KW - Tomography, X-Ray Computed
KW - Comparative Study
KW - Journal Article
U2 - 10.1093/annonc/mdl374
DO - 10.1093/annonc/mdl374
M3 - Journal article
C2 - 17060487
VL - 18
SP - 338
EP - 345
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 2
ER -
ID: 167431633